Successful delivery of TTX-MC138 to metastatic sites has been demonstrated in preclinical studies (as shown in the images below):
Click on the image above to enlarge
Images above: TTX-MC138 accumulation in metastatic lesions (TTX-MC138 accumulates in distant organs & the foci of accumulation are co-localized with the metastatic lesions).
Top row: Under heading of Metastasis on the upper left - Imaging of metastatic burden (bioluminescence imaging) in excised organs (Lymph node, Lungs, Bone).
Bottom row: Under heading of TTX-MC138 on the lower left - Fluorescence intensity in metastatic lesions in the same excised organs was associated with high uptake of TTX-MC138. Additional organs (liver, kidney and spleen) demonstrated expected high uptake of TTX-MC138 based on the natural pathway of metabolism and excretion of the nanoparticles.
Top row: Under heading of Metastasis on the upper left - Imaging of metastatic burden (bioluminescence imaging) in excised organs (Lymph node, Lungs, Bone).
Bottom row: Under heading of TTX-MC138 on the lower left - Fluorescence intensity in metastatic lesions in the same excised organs was associated with high uptake of TTX-MC138. Additional organs (liver, kidney and spleen) demonstrated expected high uptake of TTX-MC138 based on the natural pathway of metabolism and excretion of the nanoparticles.
Click on the image above to enlarge
Image above: (TTX-MC138 accumulation in metastatic lesions in brain)
Left image: (Under heading of Metastasis) - Imaging of metastatic tumor lesions (bioluminescence imaging) in brain
Right Image: (Under heading of TTX-MC138) - Presence of TTX-MC138 shown via fluorescence in the same metastatic lesions in the brain
Left image: (Under heading of Metastasis) - Imaging of metastatic tumor lesions (bioluminescence imaging) in brain
Right Image: (Under heading of TTX-MC138) - Presence of TTX-MC138 shown via fluorescence in the same metastatic lesions in the brain
Proof of Delivery to Metastatic Sites with Ferumoxytol (nanoparticles similar to the ones used in TTX-MC138)
The red arrows in the images below demonstrate that patients with metastatic lesions in the brain (images D, E, F) had an accumulation of nanoparticles in the lesions immediately after injection (image E) of ferumoxytol (iron-oxide nanoparticle formulation similar to the nanoparticles in TTX-MC138) and continued to accumulate 24 hours later shown by the darkening of the lesions (image F).
The red arrows in the images below demonstrate that patients with metastatic lesions in the brain (images D, E, F) had an accumulation of nanoparticles in the lesions immediately after injection (image E) of ferumoxytol (iron-oxide nanoparticle formulation similar to the nanoparticles in TTX-MC138) and continued to accumulate 24 hours later shown by the darkening of the lesions (image F).
Click on the image above to enlarge
The FDA has not evaluated or approved TTX-MC138 and it is currently not available for patient use.